Table 1. Baseline characteristics.
| Characteristics | Values (%) | |
|---|---|---|
| Age |
Median (range) |
48.4 (29.9–74.5) |
| HER2 status (N, %) | IHC (3+) | 93 (74) |
| |
IHC (2+) and FISH (+) |
32 (26) |
| Estrogen receptor status (N, %) | Positive | 55 (44) |
| |
Negative |
70 (56) |
| Progesterone status (N, %) | Positive | 40 (32) |
| |
Negative |
85 (68) |
| HER3 status (N, %) | Positive | 34 (30) |
| |
Negative |
78 (70) |
| PTEN status (N, %) | Positive | 92 (81) |
| |
Negative (loss) |
22 (19) |
| EGFR (N, %) | Positive | 39 (48) |
| |
Negative |
42 (52) |
| Disease status | Relapsed | 81 (64.8) |
| |
Initially metastatic |
44 (35.2) |
| Prior treatments (N, %) | Surgery | 86 (68.8) |
| Neoadjuvant chemotherapy | 12 (9.6) | |
| Adjuvant chemotherapy | 69 (55.2) | |
| |
Adjuvant radiation therapy |
67 (53.6) |
| No. of metastatic sites | 1 | 72 (57.6) |
| 2 | 34 (27.2) | |
| 3 | 15 (12.0) | |
| |
⩾4 |
4 (3.2) |
| Sites of metastasis (N, %) | Lymph node | 46 (36.8) |
| Lung and/or pleura | 46 (36.8) | |
| Liver | 30 (24.0) | |
| Brain | 10 (8.0) | |
| Bone | 43 (34.4) | |
| |
Others |
10 (8.0) |
| ECOG performance status | 0 or 1 | 110 (88) |
| |
2 |
15 (12) |
| Treatment regimen | Triweekly paclitaxel+trastuzumab | 38 (30) |
| Triweekly docetaxel+trastuzumab | 87 (70) | |
Abbreviations: ECOG=Eastern Cooperative Oncology Group; EFGR=epidermal growth factor receptor; HER=human epidermal growth factor receptor; IHC=immunohistochemistry.